Abstract
Diabetes is one of the main economic burdens in health care, which threatens to worsen dramatically if prevalence forecasts are correct. What makes diabetes harmful is the multi-organ distribution of its microvascular and macrovascular complications. Regenerative medicine with cellular therapy could be the dam against life-threatening or life-altering complications. Bone marrow-derived stem cells are putative candidates to achieve this goal. Unfortunately, the bone marrow itself is affected by diabetes, as it can develop a microangiopathy and neuropathy similar to other body tissues. Neuropathy leads to impaired stem cell mobilization from marrow, the so-called mobilopathy. Here, we review the role of bone marrow-derived stem cells in diabetes: how they are affected by compromised bone marrow integrity, how they contribute to other diabetic complications, and how they can be used as a treatment for these. Eventually, we suggest new tactics to optimize stem cell therapy.
| Original language | English |
|---|---|
| Article number | 43 |
| Number of pages | 12 |
| Journal | Current diabetes reports |
| Volume | 16 |
| Issue number | 5 |
| Early online date | 30 Mar 2016 |
| DOIs | |
| Publication status | Published - 1 May 2016 |
Keywords
- Bone marrow
- Cell regenerative therapy
- Diabetes
- Diabetic complications
- Microangiopathy
- Stem cells
Access to Document
- art%3A10.1007%2Fs11892-016-0730-x
This is the final published version of the article (version of record). It first appeared online via Current Medicine Group at http://dx.doi.org/ 10.1007/s11892-016-0730-x. Please refer to any applicable terms of use of the publisher.